Is RECIST used in clinical practice?
Though the RECIST criteria are intended for use in the clinical trial setting, oncologists increasingly rely on RECIST based measurements to make clinical management and therapeutic decisions in daily clinical practice.
What is the difference between RECIST and iRECIST?
RECIST 1.1 describes how to manage lesions that have become so small they cannot be measured. iRECIST adds an additional element, as progression is only confirmed at the “next assessment”, and so the question arises of whether iCPD can be assigned If there is an intervening NE between iUPD and what would be iCPD.
What is a target lesion in RECIST?
Assessment of pathological lymph nodes is now incorporated: nodes. with a short axis of P15 mm are considered measurable and assessable as target lesions. The short axis measurement should be included in the sum of lesions in calculation of. tumour response. Nodes that shrink to <10 mm short axis are considered normal.
What is SLD in RECIST criteria?
In RECIST 1.0, up to ten lesions should be measured, up to five per organ (target lesions). The sum of the longest diameter of the target lesions (SLD) is calculated. At each time point, the same target lesions are to be measured.
What is Pseudoprogression in immunotherapy?
Pseudoprogression is a phenomenon in which an initial increase in tumor size is observed or new lesions appear, followed by a decrease in tumor burden; this phenomenon can benefit patients receiving immunotherapy but often leads to premature discontinuation of treatment owing to the false judgment of progression.
What is Recist criteria for immunotherapy assessment?
Table 1
| RECIST 1.1 | |
|---|---|
| Definitions of measurable and non-measurable disease; numbers and site of target disease | Measurable lesions are ≥10 mm in diameter (≥15 mm for nodal lesions); maximum of five lesions (two per organ); all other disease is considered non-target (must be ≥10 mm in short axis for nodal disease) |